PHARMACY

McKesson Q2 revenues up 36%

BY Michael Johnsen

SAN FRANCISCO — McKesson on Tuesday reported that revenues for the second quarter ended Sept. 30 were $44.8 billion, up 36% compared with the year-ago period.  
 
“McKesson delivered another quarter of solid results reflecting strong execution across our business. We are very pleased with our performance for the first half of Fiscal 2015,” said John Hammergren, chairman and CEO.  “We continue to expect Adjusted Earnings per diluted share from continuing operations of $10.50 to $10.90 for the fiscal year ending March 31, 2015.”
 
Distribution Solutions revenues were $44 billion, up 37% for the quarter on a reported and constant currency basis, mainly driven by the contribution from the recent acquisition of Celesio and market growth.
 
North America pharmaceutical distribution and services revenues, which include results from U.S. Pharmaceutical, McKesson Canada and McKesson Specialty Health, were up 14% as reported and 15% on a constant currency basis for the quarter, reflecting continued demand for two recently launched drugs for the treatment of Hepatitis C.    
 
International pharmaceutical distribution and services revenues were $7.3 billion, an increase of 4% on the underlying results of Celesio on a constant currency basis.  
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

MinuteClinic debuts Rhode Island’s first retail medical clinics

BY Antoinette Alexander

WOONSOCKET, R.I. — MinuteClinic, the retail medical clinic of CVS Health, opened its first location in Rhode Island on Wednesday inside the CVS/pharmacy store in Woonsocket. Two more walk-in clinics will begin seeing patients Thursday in CVS/pharmacy locations in Cranston and Wakefield.

The Rhode Island clinics are part of MinuteClinic’s plan to add 150 clinics nationwide in 2014. With the openings this week, there will be 87 MinuteClinic locations in New England inside select CVS/pharmacy stores in Connecticut, Massachusetts, Rhode Island and New Hampshire. In total, MinuteClinic currently operates more than 940 locations in 30 states.

“MinuteClinic is the latest innovation CVS Health is bringing to its home state to help expand access to high quality care and lower costs,” said Andrew Sussman, president, MinuteClinic and SVP/associate chief medical officer, CVS Health. “As we have experienced elsewhere in New England and across the United States, MinuteClinic can support the primary care medical model by offering services at convenient locations near where patients live and work and at times when traditional options may not be available.”

The Rhode Island clinics are included in a clinical collaboration between MinuteClinic and Lifespan to enhance continuity of care with the primary care community. Lifespan is Rhode Island’s largest health system with a network of more than 1,800 affiliated physicians throughout the state. Both organizations will integrate their electronic medical records to further promote exchange of clinical information, with patients’ permission.

MinuteClinic also will be collaborating with the Rhode Island Free Clinic, providing care for free to its patients, as part of its overall commitment to increasing access to affordable health care in Rhode Island. CVS Health already provides free medications for these patients at several CVS/pharmacy locations in the state.

“The support of MinuteClinic nurse practitioners and physician assistants in providing care to our patients, will be a great complement to the quality care provided at Rhode Island Free Clinic,” said Marie Ghazal, CEO, Rhode Island Free Clinic. “Overall, MinuteClinic will also increase access to care for uninsured Rhode Islanders, promote more patients to find a primary care physician and help to reduce costs to the health care system in our state.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

FDA grants approval to Obizur

BY Ryan Chavis

SILVER SPRING, Md. — The Food and Drug Administration last week announced approval for Obizur [antihemophilic factor (recombinant), porcine sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A. 
 
The disorder is rare and potentially life threatening. It's caused by the development of antibodies directed against the body's own FVIII, which is a protein important for blood clotting. When a person's blood doesn't clot like it normally should, excessive bleeding can spontaneously occur or will happen after an injury or a surgical procedure. 
 
“The approval of this product provides an important therapeutic option for use in the care of patients with this rare disease,” said Karen Midthun, MD, director of FDA’s Center for Biologics Evaluation and Research.
 
Obizur is classified as an orphan drug by the FDA because of its use to treat a rare disease or condition. The drug is manufactured by Baxter Healthcare Corp. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?